CYTOKINETICS, INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-09-30 was 195.95K shares.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-09-30 was 27.39K shares.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-06-30 was 1.49K shares.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-03-31 was 33.44K shares, a 8474.87% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2011 was 16.00K shares, a 90.93% decline from fiscal 2010.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2010 was 176.43K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2017-09-30 | 195.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | |
| 2015-09-30 | 27.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | |
| 2015-06-30 | 1.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | |
| 2015-03-31 | 33.44K shares 10-Q · filed 2015-05-04 | |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | |
| 2014-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | |
| 2014-03-31 | 390.00 shares 10-Q · filed 2014-05-07 | |
| 2013-09-30 | 20.69K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | |
| 2011-12-31 | 16.00K shares 10-K · filed 2013-03-15 | |
| 2010-12-31 | 176.43K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |